EUROBIO SCIENTIFIC : RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025

FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION First-half revenue up 5% to €84.5 millionContinuation of the Group’s strategy: Proprietary products: 37% of revenueInternational...

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leaderCreation...